Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with
progressive regional or metastatic cancer of the urothelium. Sorafenib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow
to the tumor.